| 药品通用名/英文 |
NDC号/批准号 |
商标名 |
成份名 |
剂型 |
公司/生产厂 |
上市国/产地 |
规格/包装规格 |
备注 |
操作 |
| 布利替尼片 |
|
ALUNBRIG |
brigatinib |
tablet |
Takeda Pharma A/S/Takeda Austria GmbH （Penn Pharmaceutical Services Limited.） |
Danmark/Danmark（Storbritannien） |
30mg*56，112tablets/box：30mg*60，120tablets/bottle |
|
请先登录 |
| 布利替尼片 |
|
ALUNBRIG |
brigatinib |
tablet |
Takeda Pharma A/S/Takeda Austria GmbH （Penn Pharmaceutical Services Limited.） |
Danmark/Danmark（Storbritannien） |
90mg*7，28tablets/box：90mg*7，30tablets/bottle |
|
请先登录 |
| 布利替尼片 |
|
ALUNBRIG |
brigatinib |
tablet |
Takeda Pharma A/S/Takeda Austria GmbH （Penn Pharmaceutical Services Limited.） |
Danmark/Danmark（Storbritannien） |
180mg*28，21tablets/box：180mg*28，tablets/bottle |
|
请先登录 |
| 布利替尼片 |
76189-113-18 |
ALUNBRIG |
brigatinib |
tablet |
ARIAD Pharmaceuticals, Inc., |
USA |
30mg*180tablets/bottle |
|
请先登录 |
| 布利替尼片 |
76189-113-21 |
ALUNBRIG |
brigatinib |
tablet |
ARIAD Pharmaceuticals, Inc., |
USA |
30mg*21tablets/bottle |
|
请先登录 |
| 布利替尼片 |
HK-66119 |
ALUNBRIG |
brigatinib |
tablet |
TAKEDA PHARMACEUTICALS (HONG KONG) LIMITED |
HONG KONG |
180mg |
|
请先登录 |
| 布利替尼片 |
HK-66120 |
ALUNBRIG |
brigatinib |
tablet |
TAKEDA PHARMACEUTICALS (HONG KONG) LIMITED |
HONG KONG |
30mg |
|
请先登录 |
| 布利替尼片 |
HK-66121 |
ALUNBRIG |
brigatinib |
tablet |
TAKEDA PHARMACEUTICALS (HONG KONG) LIMITED |
HONG KONG |
90mg |
|
请先登录 |
| 注射用阿维鲁单抗 |
HK-65956 |
Bavencio |
avelumab |
injection |
MERCK PHARMACEUTICAL (HK) LIMITED |
HONG KONG |
|
|
请先登录 |
| 注射用阿维鲁单抗 |
44087-3535-1 |
Bavencio |
avelumab |
injection |
EMD Serono, Inc./Merck KGaA |
USA/Germany |
200 mg/10 mL
(20 mg/mL）/vial |
|
请先登录 |
| 注射用阿维鲁单抗 |
|
Bavencio |
avelumab |
injection |
ファイザー株式会社 /メルクバイオファーマ株式会社 |
JP |
200 mg/10 mL
(20 mg/mL）/vial |
|
请先登录 |
| 注射用阿维鲁单抗 |
|
Bavencio |
avelumab |
injection |
Merck Europe B.V/Merck Serono S.p.A |
Nederland/Italië |
200 mg/10 mL
(20 mg/mL）/vial |
|
请先登录 |
| 注射用伊珠单抗奥加米星 |
0008-0100-01 |
Besponsa |
inotuzumab ozogamicin |
injection |
WYETH PHARMACEUTICALS LLC, A SUBSIDIARY OF PFIZER INC. |
USA |
（0.25mg/ 1 mL）0.9 mg/4ml/vial/box |
|
请先登录 |
| 注射用伊珠单抗奥加米星 |
|
Besponsa |
inotuzumab ozogamicin |
injection |
ファイザー株式会社 |
JP |
1MG/1ml/vial/box |
|
请先登录 |
| 注射用伊珠单抗奥加米星 |
|
Besponsa |
inotuzumab ozogamicin |
injection |
Pfizer Limited/Pfizer Ireland Pharmaceuticals |
UK/
Ireland |
1MG/1ml/vial/box |
|
请先登录 |
| 注射用伊珠单抗奥加米星 |
|
Besponsa |
inotuzumab ozogamicin |
injection |
Pfizer Europe MA EEIG/Pfizer Ireland Pharmaceuticals
|
Ireland |
1MG/1ml/vial/box |
|
请先登录 |
| 注射用伊珠单抗奥加米星 |
|
Besponsa |
inotuzumab ozogamicin |
injection |
Pfizer/Pfizer Ireland Pharmaceuticals
|
FRANCE/Irlande |
1MG/1ml/vial/box |
|
请先登录 |
| 注射用伊珠单抗奥加米星 |
|
Besponsa |
inotuzumab ozogamicin |
injection |
Pfizer Pharma GmbH/Pfizer Ireland Pharmaceuticals
|
Germany/Irlande |
1MG/1ml/vial/box |
|
请先登录 |
| 注射用伊珠单抗奥加米星 |
HK-65947 |
Besponsa |
inotuzumab ozogamicin |
injection |
PFIZER CORPORATION HONG KONG LIMITED |
HONG KONG |
1MG |
|
请先登录 |
| 阿可替尼胶囊 |
0310-0512-60 |
CALQUENCE |
acalabrutinib |
capsule |
AstraZeneca Pharmaceuticals LP |
USA |
100mg*60tablets/bottle |
|
请先登录 |
| 阿可替尼胶囊 |
310-0512-28 |
CALQUENCE |
acalabrutinib |
capsule |
AstraZeneca Pharmaceuticals LP |
USA |
100mg*28tablets/bottle |
|
请先登录 |
| 甲磺酸伊那尼布片 |
59572-705-30 |
IDHIFA |
enasidenib mesylate |
tablet |
Agios Pharmaceuticals,/ Celgene Corporation |
USA |
50mg*30tablets/bottle |
|
请先登录 |
| 甲磺酸伊那尼布片 |
59572-710-30 |
IDHIFA |
enasidenib mesylate |
tablet |
Agios Pharmaceuticals,/ Celgene Corporation |
USA |
100mg*30tablets/bottle |
|
请先登录 |
| 注射用度伐鲁单抗 |
0310-4500-12 |
Imfinzi |
durvalumab |
injection |
AstraZeneca Pharmaceuticals LP/AstraZeneca UK Limited |
USA/UK |
120 mg/2.4 mL
(50 mg/mL)/VIAL/BOX |
|
请先登录 |
| 注射用度伐鲁单抗 |
0310-4611-50 |
Imfinzi |
durvalumab |
injection |
AstraZeneca Pharmaceuticals LP/AstraZeneca UK Limited |
USA/UK |
500 mg/10 mL
(50 mg/mL)/VIAL/BOX |
|
请先登录 |
| 注射用度伐鲁单抗 |
|
Imfinzi |
durvalumab |
injection |
アストラゼネカ株式会社
|
JP |
120 mg/2.4 mL
(50 mg/mL)/VIAL/BOX |
|
请先登录 |
| 注射用度伐鲁单抗 |
|
Imfinzi |
durvalumab |
injection |
アストラゼネカ株式会社
|
JP |
500 mg/10 mL
(50 mg/mL)/VIAL/BOX |
|
请先登录 |
| 注射用度伐鲁单抗 |
|
Imfinzi |
durvalumab |
injection |
AstraZeneca UK Ltd /AstraZeneca AB |
UK/Sweden |
120 mg/2.4 mL
(50 mg/mL)/VIAL/BOX |
|
请先登录 |
| 注射用度伐鲁单抗 |
|
Imfinzi |
durvalumab |
injection |
AstraZeneca UK Ltd /AstraZeneca AB |
UK/Sweden |
500 mg/10 mL
(50 mg/mL)/VIAL/BOX |
|
请先登录 |
| 注射用度伐鲁单抗 |
|
Imfinzi |
durvalumab |
injection |
AstraZeneca AB
|
Sweden |
120 mg/2.4 mL
(50 mg/mL)/VIAL/BOX |
|
请先登录 |
400-8577-888